This paper provides a clinical deep dive into the anesthetic management of patients with Multiple Endocrine Neoplasia Type 2A (MEN2A), a rare genetic syndrome. By analyzing 33 surgeries, the researchers highlight the high-stakes "hemodynamic rollercoaster" anesthesiologists face when these patients have catecholamine-secreting tumors, offering a roadmap for safer perioperative care.
TL;DR
This retrospective study of 24 MEN2A patients underscores that surgical resection of pheochromocytomas (PHEOs) must remain the clinical priority. Performing other surgeries while a PHEO is still present significantly increases the risk of life-threatening hypertensive crises and prolonged ICU stays, requiring specialized anesthetic preparation.
What Problem Does This Paper Address?
MEN2A is a rare condition characterized by a triad of tumors: medullary thyroid carcinoma (MTC), pheochromocytoma (PHEO), and hyperparathyroidism. The most dangerous component for an anesthesiologist is the pheochromocytoma—a tumor of the adrenal glands that sporadically dumps massive amounts of catecholamines (like adrenaline) into the bloodstream.
When a patient needs surgery (for example, to remove the thyroid), the presence of an untreated PHEO can lead to "hemodynamic instability"—extreme, rapid swings in blood pressure and heart rate that can cause heart failure or stroke. While clinical guidelines suggest removing the PHEO first, there is limited data on the actual anesthetic outcomes and risks when these guidelines are or aren't followed. This paper fills that gap by sharing seven years of experience from a national rare disease center.
Methods
The researchers conducted a retrospective cohort study at the Peking Union Medical College Hospital, analyzing medical records from January 2015 to December 2021.
They categorized 33 surgeries into three distinct clinical scenarios:
- PHEO Resection: Removing the adrenal tumor itself.
- Non-PHEO Resection without PHEO: Surgeries (like thyroidectomies) performed on patients who either didn't have a PHEO or had already had it removed.
- Non-PHEO Resection with existing PHEO: The "high-risk" group where patients had active or metastatic adrenal tumors while undergoing other procedures.
The team tracked "hemodynamic events" (defined as systolic blood pressure spikes >180 mmHg or 30% above baseline), preoperative medication (alpha-blockers), and recovery metrics like ICU and hospital length of stay.
Datasets
The study utilized a specialized clinical dataset from the Peking Union Medical College Hospital’s medical record system.
- Sample Size: 24 patients, 33 total surgeries.
- Demographics: 13 female, 11 male; average age ~30 years.
- Clinical Data: Included 24-hour urinary catecholamine levels, metanephrine (MN), and nor-metanephrine (NMN) levels.
Key Insights and Ideas
- The "PHEO First" Rule is Non-Negotiable: The data strongly supports the guideline that adrenal tumors should be resected before tackling thyroid issues. Patients who had their PHEO removed first had significantly more stable surgeries later.
- Alpha-Blockade is Not a Magic Bullet: Even with 2–4 weeks of preoperative alpha-blockers (meds to stabilize blood pressure), 45% of patients undergoing PHEO resection still experienced significant blood pressure spikes during surgery.
- The Danger of Metastatic PHEO: The most harrowing case involved a patient with metastatic PHEO undergoing a thyroidectomy. Post-surgery, the patient suffered a "pheochromocytoma crisis" and catecholamine-induced heart failure, resulting in a 430-hour (nearly 18-day) ICU stay.
- Predictive Biomarkers: High preoperative 24-hour urinary catecholamine levels were correlated with longer postoperative ICU stays, serving as a potential "red flag" for anesthesiologists.
Key Results
- Hemodynamic Instability: In the PHEO resection group, 20% of surgeries saw blood pressure exceed 180 mmHg, and 45% saw spikes >30% above baseline.
- Recovery Time: Patients undergoing PHEO resection stayed in the hospital significantly longer than those undergoing non-PHEO surgeries without an active tumor (5.8 days vs. 4.3 days; P = 0.031).
- Tumor Size Matters: Hypertensive crises during surgery were most common in patients with adrenal tumors larger than 5 cm.
- Safety of Non-PHEO Surgery: For patients without an active PHEO, surgeries were remarkably stable, suggesting that once the adrenal threat is removed, these patients can be managed like standard surgical cases.
Limitations and Future Work
- Small Sample Size: While 24 patients is a significant cohort for a rare disease, it limits the statistical power of the findings.
- Missing Genetic Data: RET proto-oncogene mutation analysis—the gold standard for MEN2A diagnosis—was not available for all patients in this retrospective set.
- Single-Center Bias: The results reflect the protocols of one high-volume center; multi-center studies are needed to create universal anesthetic guidelines.
- Future Directions: The authors suggest that future research should focus on refining the "alpha-blockade" protocol and investigating if specific RET mutations correlate with more aggressive hemodynamic instability.
Summary updated